About this Research Topic
The articles collated for this issue will largely be based on presentations at the Mycology 2021 in London, which, because of the impact of COVI-19 restrictions, will be held entirely as a virtual congress.
LINK: mycologyconference.co.uk
The thematic is to combine clinical and academic mycology in one meeting and to promote networking that can ultimately make a difference to the clinical challenges of patients with fungal diseases. We welcome articles addressing the session themes of:
- Host susceptibility
- IFD prophylaxis and management in Haemato-oncology
- IFD in solid organ transplantation
- the role of mycology societies/organisations
- diagnostics - lateral flow, PCR, T2MR, resistance testing, NGS
- fungal adaptation to the host environment
- Mycobiome and NGS
- Fungal infections in CF and bronchiectasis
- Novel antifungal drugs
- Influenza, SARS-CoV-2 and aspergillosis
- Educational clinical cases
Topic editor declare the following Conflict Of Interest:
S. Agrawal - Consultancy work for, and research grants form, Gilead Sciences Ltd, Pfizer Ltd
N. Gow - research funded by Gilead Sciences.
L White - Consultancy work for Gilead Sciences Ltd, Pfizer Ltd and F2G Ltd. Diagnostic collaborations with IMMY, Bruker, Associates of Cape Cod and Dynamiker.
LINK: mycologyconference.co.uk
The thematic is to combine clinical and academic mycology in one meeting and to promote networking that can ultimately make a difference to the clinical challenges of patients with fungal diseases. We welcome articles addressing the session themes of:
- Host susceptibility
- IFD prophylaxis and management in Haemato-oncology
- IFD in solid organ transplantation
- the role of mycology societies/organisations
- diagnostics - lateral flow, PCR, T2MR, resistance testing, NGS
- fungal adaptation to the host environment
- Mycobiome and NGS
- Fungal infections in CF and bronchiectasis
- Novel antifungal drugs
- Influenza, SARS-CoV-2 and aspergillosis
- Educational clinical cases
Topic editor declare the following Conflict Of Interest:
S. Agrawal - Consultancy work for, and research grants form, Gilead Sciences Ltd, Pfizer Ltd
N. Gow - research funded by Gilead Sciences.
L White - Consultancy work for Gilead Sciences Ltd, Pfizer Ltd and F2G Ltd. Diagnostic collaborations with IMMY, Bruker, Associates of Cape Cod and Dynamiker.
Keywords: Fungal Diseases, Host Susceptibility, iFD management, COVID-19 and Fungal disease, Antifungal resistance, New Drugs, Mycobiome
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
